Literature DB >> 15901930

In vitro testing of chemosensitivity in physiological hypoxia.

Rita Grigoryan1, Nino Keshelava, Clarke Anderson, C Patrick Reynolds.   

Abstract

Highly aggressive, rapidly growing tumors are often hypoxic, owing to an inadequate supply relative to consumption of oxygen (O2) in the expanding tumor mass, or growth in tissues with physiologically low O2 concentrations (such as bone marrow). Selection of tumor cells that can grow or survive under hypoxic conditions appears from both experimental and clinical studies to impact tumor progression, response to therapy, and to increase resistance to radiation and to certain cytotoxic drugs. Therefore, the predictive value of preclinical testing of anticancer agents in cell culture might be improved by conducting testing in conditions of physiological hypoxia. We review the impact of hypoxia on anticancer drug cytotoxicity and the methods used in our laboratory to asses the cytotoxic activity of single antineoplastic drugs under conditions of physiological hypoxia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15901930     DOI: 10.1385/1-59259-869-2:087

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  5 in total

1.  National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Authors:  Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2010-10-04       Impact factor: 3.167

2.  Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.

Authors:  Michael A Sheard; Matthew V Ghent; Daniel J Cabral; Joanne C Lee; Vazgen Khankaldyyan; Lingyun Ji; Samuel Q Wu; Min H Kang; Richard Sposto; Shahab Asgharzadeh; C Patrick Reynolds
Journal:  Exp Cell Res       Date:  2015-04-03       Impact factor: 3.905

3.  The radiomimetic enediyne, 20'-deschloro-C-1027 induces inter-strand DNA crosslinks in hypoxic cells and overcomes cytotoxic radioresistance.

Authors:  Terry A Beerman; Loretta S Gawron; Ben Shen; Daniel R Kennedy
Journal:  DNA Repair (Amst)       Date:  2014-06-28

4.  Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models.

Authors:  Thinh H Nguyen; Balakrishna Koneru; Sung-Jen Wei; Wan Hsi Chen; Monish Ram Makena; Eduardo Urias; Min H Kang; C Patrick Reynolds
Journal:  Mol Cancer Ther       Date:  2019-09-04       Impact factor: 6.009

5.  The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.

Authors:  A Tagde; H Singh; M H Kang; C P Reynolds
Journal:  Blood Cancer J       Date:  2014-07-18       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.